Marta Biderman Waberski, MD
Clinical Genetics (M.D.) · Fairfax, VANPI 1164733960
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $68,058 of the $89,490 with a category attached, or 76.1%. Sanofi accounts for 94.0% of it on its own, with 7 other manufacturers making up the rest.
Across 78 payments — averaging $1147.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$84K
- Amicus Therapeutics, Inc.$5K
- AstraZeneca$129
- Chiesi USA, Inc.$116
- Biogen$59
- Soleno Therapeutics, Inc.$26
- plus $50 from 2 others
What the payments were for
- Consulting fees$8,0259%
- Speaking & faculty fees$68,05876%
- Travel & lodging$11,35913%
- Food & beverage$1,9902%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 67 | $84,142 |
| Amicus Therapeutics, Inc. | 5 | $4,970 |
| AstraZeneca | 1 | $129 |
| Chiesi USA, Inc. | 1 | $116 |
| Biogen | 1 | $59 |
| Soleno Therapeutics, Inc. | 1 | $26 |
| Biomarin Pharmaceutical Inc. | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FABRAZYME$36,754
- NEXVIAZYME$34,090
- LUMIZYME$13,733
- POMBILITI$1,330
- OPFOLDA$1,330
- CEREZYME$548
- CERDELGA$548
- ALDURAZYME$548
- KOSELUGO$129
- ELFABRIO$116
How this compares
Too few clinical genetics (m.d.) providers in Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CystadaneBetaine | 19 | $16,407 |
| Leucovorin Calcium | 12 | $647 |
Paid to pharmacies, not to this prescriber.
Other clinical genetics (m.d.) in Fairfax
- Harvey SternFairfax$139
- Arti PandyaRichmond$4K
- Natalie HauserFalls Church$320
- Matthew SnyderCharlottesville$288
- William WilsonCharlottesville$264
- Paul KruszkaCharlottesville$144
- Danielle MonteilPortsmouth$126
- Jennifer HumbersonRichmond$85
- Gulsen AkayRichmond$57
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.